28,982 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Orser Capital Management LLC

Orser Capital Management LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 28,982 shares of the medical research company's stock, valued at approximately $2,101,000. Edwards Lifesciences accounts for 1.6% of Orser Capital Management LLC's holdings, making the stock its 19th largest holding.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter valued at approximately $26,000. Vega Investment Solutions purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $27,000. Millstone Evans Group LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $30,000. Finally, Park Square Financial Group LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $44,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $0.23 during midday trading on Wednesday, hitting $77.95. The stock had a trading volume of 3,443,958 shares, compared to its average volume of 5,188,316. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The company has a market capitalization of $45.73 billion, a PE ratio of 11.18, a P/E/G ratio of 4.82 and a beta of 1.12. The firm's fifty day moving average is $73.62 and its two-hundred day moving average is $72.60.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company's revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $0.66 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on EW. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. Citigroup reissued a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Wall Street Zen downgraded Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Finally, Barclays upped their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $80.20.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This trade represents a 27.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,012 shares of company stock valued at $4,224,717 over the last 90 days. Company insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.